Download this datacard
Overview
Lobbying Costs
75,000€
Financial year: Jan 2019 - Nov 2019
Lobbyists (Full time equivalent)
1.25 Fte (2)
Lobbyists with EP accreditation
0
High-level Commission meetings
0
Lobbying Costs over the years
-
Info
Swedish Orphan Biovitrum (Sobi)
EU Transparency Register
232923831740-31 First registered on 07 Jun 2018
Goals / Remit
Sobi is a pharmaceutical company specialized in rare diseases. Our aim is to continue to develop rare disease treatments and to create access to those for patients.
We will continue to build on our strong position that covers the entire value chain for treatment of rare diseases in EMENAR and North America. Sobi offers an integrated process, from in-house research and development in protein characterisation, biologics manufacturing and industrialisation, to commercialisation of products for rare diseases. Partnering with stakeholders and facilitating effective and timely rare-disease therapy development, including an extensive and robust distribution network, creates unique opportunities for us to add value to the rare-disease field.Main EU files targeted
Health policy, primarily those related with rare disease policy and access to medicines
Address
Head Office
Tomtebodavägen 23A
Stockholm
SWEDENEU Office
Rue Neerveld, 101-103
woluwe saint lambert
BELGIUM -
People
Total lobbyists declared
2
Employment time Lobbyists 100% 1 25% 1 Lobbyists (Full time equivalent)
1.25
Lobbyists with EP accreditation
All Lobbyists with EP accreditation over time
0 accreditations were / are live (in bold) for the selected state of 16 Jun 2020
Name Start date End Date Ms Mihaela VERINGA 26 May 2022 26 May 2023 Complementary Information
None declared
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
II - In-house lobbyists and trade/business/professional associations
Subcategory
Companies & groups
-
Networking
Affiliation
Sobi is member of:
- EuropaBio
- EUCOPEMember organisations
None declared
-
Financial Data
Closed financial year
Jan 2019 - Nov 2019
Lobbying costs for closed financial year
75,000€
Other financial info
None declared
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
None
Communication activities
- European Commission Regulation on health technology assessment and amending Directive 2011/24/EU
- European Commission study on the evaluation of the EU orphan legislationOther activities
None declared
- Meetings
Meetings
None declared
- Meetings